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Abstract
Background. A recent large-scale case-control study on
analgesic nephropathy (SAN) [1] found no increased risk
of end-stage renal disease (ESRD) in users of combined
or single formulations of phenacetin-free analgesics. In a
subgroup of 22 high users, however, a dose-dependent in-
creased risk was found, which raised the question if these
patients presented or not with analgesic nephropathy (AN).
Methods. The individual questionnaires of this subgroup
of high users were reviewed, and the total lifetime intake of
different types of analgesics was calculated. For evidence
of AN, the following data were considered: (1) the amount
and type of analgesics consumed, (2) the cause of ESRD, as
diagnosed by the nephrologist in charge of the patient and
(3) renal imaging and other relevant laboratory data.
Results. This group of ESRD patients consumed on av-
erage 7.8 kg of antipyretic analgesics (range 30.8–2.7 kg)
over an average of 21.5 years (range 35–6 years). Single
analgesics were exclusively used by 12 patients (54.5%)
and combined analgesics by 5 patients (22.7%), while 5
patients used both. None of the patients was diagnosed
as having AN, and a review of the questionnaires did not
disclose evidence suggestive of AN. The possibility that,
irrespective of AN, the analgesic (ab)use contributed to the
progression of existing renal diseases cannot be answered
in the absence of well-defined criteria. The data supporting
the existence of such an analgesic-associated nephropathy
(AAN) are, however, not consistent and most likely due to
confounding by indication.
Conclusion. In a group of ESRD patients with high use of
non-phenacetin analgesics, no evidence of AN was found.
There is no evidence that (ab)use of analgesics or NSAIDs
other than phenacetin leads to a pathologically or clinically
defined renal disease that could be named AN or AAN.
Correspondence and offprint requests to: Paul Michielsen, Acacialaan 54,
Herent B3020, Belgium. E-mail: paul.michielsen@med.kuleuven.be
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Introduction
The nephrotoxicity of analgesics first came under attention
by the observation of a large number of ESRD cases in
patients abusing analgesic mixtures containing phenacetin.
This new disease was named phenacetin nephropathy. The
exclusive role of phenacetin as cause of analgesic nephropa-
thy (AN) was later challenged, first by the group of Kincaid-
Smith [2], later by De Broe and Elseviers [3,4]. This re-
sulted in a redefinition of AN as ‘a disease resulting from
the habitual consumption over several years of a mixture
containing at least two antipyretic analgesics and usually
codeine or caffeine’. This new definition gained credibility
after endorsement in 1996 by a Position Paper of the pres-
tigious National Kidney Foundation [5]. Notwithstanding
the questionable nature of the data supporting this new def-
inition [6–9], it was accepted without restriction by lead-
ing nephrologists [10], which resulted in an official state-
ment of the professional German-speaking associations of
Nephrology at their 1996 Congress in Berlin [11]. The con-
troversy persisted, however, mainly because of the difficulty
in excluding the previous phenacetin intake [12,13]. This
resulted in the setup of a large-scale case-control study
in Germany and Austria [study on analgesic nephropathy
(SAN)], its main objective being the control of such bias
by including only patients younger than 50 years. The pro-
tocol of the study was published in detail [14], and in the
recently published results [1] no evidence of an increased
ESRD risk was found in users of combined or single formu-
lations of phenacetin-free analgesics. In a subgroup of high
users, however, a dose-dependent significantly increased
risk of ESRD was found (Table 1). The present study was
undertaken at the request of the SAN supervising Scientific
Advisory Committee (SAC) to examine the clinical signif-
icance of this finding, and more specifically to determine if
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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Table 1. Adjusted relative risk of ESRD by increasing cumulative lifetime
dose of analgesic use at index date 3 (5 years before ESRD)a
Grams Cases Controls OR (95% CI)
Low use 546 2030 1.00 (referent)
<500 278 1365 0.75 (0.64–0.88)
501–1000 41 133 1.10 (0.77–1.59)
1001–1500 10 47 0.76 (0.38–1.52)
1501–2000 6 19 1.03 (0.40–2.62)
2001–2500 4 9 1.50 (0.48–4.74)
2501–3000 3 8 1.35 (0.37–4.94)
≥3001 19 11 6.02 (2.83–12.81
aData from the SAN study [1]. Reproduced with permission.
in this subgroup of high users ESRD was due to AN and re-
lated to heavy consumption of mixed antipyretic analgesics
as defined in [5].
Methods
In the SAN study, all antipyretic analgesics, non-steroidal
anti-inflammatory agents (NSAIDs) and additives such as
caffeine and codeine are included in the calculation, and
the consumption is calculated at different time intervals
before ESRD. In order to minimize the risk of confounding
by indication, the cumulative lifetime consumption until
5 years before admission for dialysis (index date 3) was
selected for the final analysis. As shown in Table 1, the
so-defined consumption exceeded 2500 g in 22 cases. As
the present study is aimed at examining the evidence of AN
in this subgroup of 22 high consumers, the analgesic intake
was recalculated to bring it in line with the definition of
classical AN [5,15]. The following criteria were applied:
1. The total lifetime intake of analgesics, until admission
for dialysis (index date 1), was taken into account.
2. Only antipyretic analgesics (ASA, salicylates, amin-
ophenazone, acetaminophen, etc.) were considered;
NSAIDs such as diclofenac, ibuprofen, naproxen, etc.
were not included.
3. Combined analgesics (Combi) were defined as the com-
bination of at least two antipyretic analgesics.
4. The intake of caffeine, codeine and other additives was
excluded from the calculation of the analgesic intake.
5. For total intake calculation, only the intake exceeding
6 months was considered. Occasional intakes for minor
transitory discomforts were not included.
Criteria for diagnosis of AN
The questionnaires completed by the interviewers and the
physicians responsible for the dialysis of these 22 cases
were further reviewed for evidence of AN by one of
the authors (P.M.). As no autopsy data were available on
these 22 cases, the diagnosis of AN was evaluated on the
following data.
1. The cause of the ESRD, as estimated by the physician in
charge of the patient.
Table 2. Number of patients in each category of analgesic consumption,









2501–3000 3 0 2
3001–3500 5 2 1
3501–4000 2 4 3
4001–5000 4 3 3
5001–6000 2 0 1
>6000 6 13 12
aData from the SAN study [1].
bData obtained from the questionnaires.
2. Imaging data compatible with papillary necrosis [16].
3. Detailed history of past (ab)use of antipyretic analgesics.
Results
Analgesic intake
As shown in Table 2, the inclusion in the calculation of the
last 5 years before ESRD markedly increased the estimated
lifetime consumption, but the strict restriction to antipyretic
analgesics had only a marginal effect.
The lifetime consumption of antipyretic analgesics by
these 22 cases averaged 7.8 kg (range 30.8–2.7), which is
within the range of abuse reported as having induced AN.
In Table 3, the patients/cases are separated in three groups
according to the type of antipyretic analgesics consumed:
only five patients had used exclusively combination for-
mulations (Group I) and their average intake was 12.6 kg
(range 30.8–2.7). Another five patients had used both single
and combination formulations (Group II), with an average
intake of 5.4 kg (range 7.5–4.1). Single preparations were
used by 12 cases (Group III) and their average intake was
6.8 kg (range 19.2–2.9). NSAIDs were taken by seven
patients: mefenamic acid by patients Id, Ie, IIc; ibuprofen
by patients IIb, IIIa, IIId; diclofenac by patient IIIe (data not
shown).
The compulsive daily intake of a large number of tablets
over a prolonged period of time is a characteristic of
phenacetin abuse [17]. In our patients, a continuous daily
intake during 1 year or more was only found in three users
of combined analgesics and eight users of single analgesics
and the daily intake of tablets was much lower than reported
for phenacetin-containing Combis (Table 3).
Diagnosis of AN
For a study aimed at evaluating the causal nature of a re-
lationship between high intake of combined analgesics and
AN, an unequivocal definition of AN and reliable criteria of
diagnosis are essential. Based on autopsy observations in
patients abusing phenacetin-containing mixed analgesics,
AN was defined as characterized by papillary necrosis and
secondary parenchymal lesions. This papillary necrosis is
linked to the presence of capillary sclerosis, a specific
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Table 3. Lifetime antipyretic analgesic consumption for users of Combi(I), mono(III) or both (II)
Antipyretic analgesics
Combinations Single products
Cases Diagnosis Gram Tablets/day Days/year Years Gram Tablets/day Days/year Years
Ia Unclear 30 812 6 365 32
Ib Polycystic kidneys 12 318 15 365 6
Ic Unclear 10 767 8 365 11
Id Polycystic kidneys 6 464 3 144 34
Ie Unclear 2 658 3–4 12–30 15
IIa Diabetic nephropathy 803 3–4 72–208 7 6 721 2–10 156–208 24
IIb Diabetic nephropathy 5 254 4 108 24 875 3 25 24
IIc Unclear 234 2 10 28 4 858 3 10–56 35
IId Focal glomerulosclerosis 1 002 4 24 24 3 080 4 48 26
IIe Diabetic nephropathy 1 390 2 12–30 30 2 684 2 12–90 30
IIIa Diabetic nephropathy 19 208 1–10 14–365 16
IIIb Unclear 14 933 2–10 6–365 14
IIIc Diabetic nephropathy 6 879 2–3 7–365 28
IIId Polycystic kidneys 6 547 2 365 19
IIIe Diabetic nephropathy 6 436 2–3 42–365 25
IIIf IgA nephropathy 6 193 4–2 365 20
IIIg Lupus nephritis 4 668 2–4 36–104 19
IIIh Diabetic nephropathy 3 689 1–3 24–365 30
IIIi Amyloidosis 3 628 2 156 25
IIIj Malignant hypertension 3 503 3–4 182 17
IIIk Glomerulonephritis 3 380 3 365 7
IIIl Renal infarction 2 870 2 4–147 20
Cause of ESRD as reported in the medical questionnaire.
lesion of the capillaries in the papillae and the mucosa
of the pyelon and ureter. In the clinical setting, as substitute
for a pathological diagnosis, a CT scan finding of bilater-
ally decreased renal mass combined with bumpy contours
and, in particular, papillary calcifications became accepted
as diagnostic of AN [18,19]. Such renal lesions have been
claimed to result from the abuse of combined analgesics
with or without phenacetin [5,15,16].
The diseases considered responsible for ESRD are men-
tioned in Table 3. In 17 patients a clear diagnosis is indi-
cated, consistent with the progression to ESRD; for five
cases the diagnosis was reported as unclear, but none of
the patients was diagnosed as presenting AN. In addition
to diabetic nephropathy, which was reported as responsi-
ble for ESRD, patient IIIe had undergone a right nephrec-
tomy for nephrolithiasis and pyonephrosis. In the absence
of computer tomography, available echography data were
reviewed for evidence suggesting papillary necrosis. None
of the patients presented small indented kidneys with pap-
illary calcifications (Table 4).
The clinical data of the cases with unclear diagnosis were
as follows:
Case Ia is a 44-year-old woman who had taken com-
bined analgesics for more than 30 years. She was a
regular heroin and cocaine user for 25 years. The asso-
ciation of proteinuria >2 g/24 h, a rapidly progressing
renal failure and a biopsy finding of extreme tubular
atrophy with interstitial fibrosis may be suggestive of
‘heroin nephropathy’. Echography did not suggest AN.
Case Ic is a 46-year-old woman who started tak-
ing combined analgesics at age 35 for prevention of
headache. There are inconsistencies in the medical his-
tory as reported in the questionnaire. Objective data are
scarce. Proteinuria is indicated as positive but without
mentioning the degree. Echography disclosed small
bumpy kidneys without calcifications. The following
ESRD risk factors were present: hypertension, obesity
(BMI 33), heavy smoker since age 17. The available
data are insufficient to eliminate or confirm a diagnosis
of AN.
Case Ie is a 42-year-old patient with a long-standing
history of kidneys reduced in size, proteinuria, hyper-
tension and toxaemia of pregnancy. There are no rea-
sons to suspect AN. This patient also consumed 799 g
of mefenamic acid over 26 years.
Case IIc is a 47-year-old woman with a long-term his-
tory of intermittent use of various analgesics. She pre-
sented hypertension and proteinuria >2 g/24 h. There
are no reasons to suspect AN. This patient consumed
1032 g of mefenamic acid over 24 years.
Case IIIb is a 44-year-old man with insulin-dependent
diabetes mellitus since the age of 3 years. He had a
heart transplant and was suspected of cyclosporine
toxicity.
Discussion
The data from the study questionnaires are unequivocal:
In that none of the 22 patients in this group of high analgesic





Table 4. Clinical characteristics and risk factors for ESRD
Proteinuria Echography Smoking
Case Sex Intake of antipyretic
analgesics (g)









Ia F 30 812 Positive + − − + 23.14 Yes Yes 60
Ib F 12 318 Negative − − − + 26.26 Yes Yes 15.5
Ic F 10 767 +? +? + + − + 33.02 Yes Yes 28
Id M 6 464 Not available − − − + 22.63
Ie F 2 658 Positive + − − + 22.28 Yes 13.5
IIa M 7 524 Positive − + − + 22.41
IIb F 6 129 Not available − − − − 33.95 Yes 4.5
IIc F 5 092 Positive + − − + 25.22 Yes 0.25
IId M 4 082 Positive − − − + 21.43 Yes Yes 18.75
IIe M 4 074 Positive + − + + 19.34 Yes Yes 18
IIIa M 19 208 Positive Not available + 23.29 Yes Yes 33
IIIb M 14 933 Not available Not available + 23.37 Yes Yes 20
IIIc M 6 879 Positive − − − + 28.58 Yes 57.5
IIId M 6 547 Negative − − − + 25.93
IIIe F 6 436 Positive − − − + 31.20
IIIf M 6 193 Positive + − − + 36.59
IIIg F 4 668 Positive + − − + 23.34
IIIh M 3 689 Positive − − − + 29.63 Yes 18
IIIi F 3 628 Not available + − − + 14.82
IIIj M 3 503 Positive + − − + 24.49 Yes Yes 11
IIIk M 3 380 Positive + − − + 30.78
IIIl M 2 870 Negative − − − + 32.41 Yes 14
Data from the questionnaires.
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Has the diagnosis of AN been missed? Without autopsy
and without a CT scan this cannot be excluded, but in most
patients there was clear evidence of another diagnosis, and
in the patients with unclear diagnosis there was no evidence
of papillary necrosis. A missed diagnosis of AN is unlikely
for the following additional reasons:
• It is true that a clinical diagnosis of AN can be difficult,
but in most studies claiming the toxicity of combined
analgesics, the diagnosis of AN was also a clinical diag-
nosis. It is unlikely that the nephrologists in charge of the
patients would have lost their diagnostic skills, especially
in Germany and Austria, countries with a high degree of
awareness of AN among both the medical profession and
the public.
• Analgesic intake did not correspond to the pattern
deemed responsible for AN.
• In ESRD patients without clear diagnosis, a recent large-
scale epidemiological study concluded that CT findings
similar to those described by De Broe [18] were present
only in a minority of heavy analgesic users [20], partic-
ularly when phenacetin intake was excluded. The data
from the present study are consistent with this conclu-
sion.
• Also consistent with our study are the results of a
population-wide case-control study in Sweden [21]. In
this study, AN nephropathy as described by Elseviers
and De Broe [18] was not found in patients with newly
diagnosed renal failure.
• At the request of the SAN supervising scientific com-
mittee, Mihatsch conducted in 2006 an exact replica-
tion of his autopsy study performed in 1978–1980 in
Basel [22]. The conclusion of this new study was that
AN had disappeared [23]. It is unlikely that AN would
have disappeared in Basel, but not in Germany and
Austria.
Altogether, these arguments lead to the conclusion that
the diagnosis of the referring physicians can be assumed to
be correct and that the dose-dependent correlation found in
the SAN study between high analgesic intake and ESRD
was not due to AN. This, however, raises the question
of the adequacy of the design of the SAN study. The ti-
tle of the SAN study [1] suggests that it is only relevant
to young age, as previous phenacetin (ab)use was elimi-
nated by setting the age limit at 50 years. Did this age limit
preclude the necessary massive consumption of analgesics
and/or was the duration of observation sufficient to develop
AN?
In most studies the cut-off point, defining the cumulative
intake of analgesics correlated with an increased risk of
AN, is 1 kg or 5000 pills lifetime use [19]. In the subgroup
of high users investigated in the present study, the lowest
lifetime intake was 3 kg, the maximum 30 kg and the dura-
tion of abuse varied between 6 and 32 years. The age limit
of 50 years was obviously more than adequate to allow for
the massive consumption of analgesics reported as having
caused AN.
The second question concerns the delay needed for the
development of AN. In the definition of AN as a con-
sequence of abuse of unspecified mixed antipyretic anal-
gesics, it is assumed that the earlier observed phenacetin
toxicity was only part of a broader toxicity involving all
mixed antipyretic analgesics. If this hypothesis were cor-
rect, the massive use of combined analgesics could be ex-
pected to induce the same lesions within the same time limit
as if these combined analgesics contained phenacetin. As
long as phenacetin-containing analgesics were still used,
AN was a disease of middle age. Autopsy data from Basel
[24] indicate that in the years 1948–1957, the maximal in-
crease in the number of cases of chronic interstitial nephritis
occurred in the age group of 31–40 years. Australian data
published in 1970 [2] indicate that more than half of the
patients with AN were below 50 years of age. The obvi-
ous explanation for the present-day finding of AN as a
disease of older age is that these cases, as seen today, are
only late consequences of previous phenacetin abuse. This
is consistent with the parallel modification of the autopsy
findings. As described by Mihatsch, the normal sized kid-
neys shedding necrotic papillae, routinely found at autopsy
in the sixties, evolved progressively to the present-day find-
ing of small bumped kidneys with papillary calcifications
[25,26].
It can be concluded that the relevance of the SAN study
was not limited to younger age and that it was adequate
to detect AN if it had occurred. Taken together with the
disappearance of AN from the autopsy studies in Basel, the
present study leads to the inescapable conclusion that AN
has disappeared with the ban of phenacetin and is no longer
a public health problem. The term AN was introduced to
include unspecified antipyretic analgesics or a combina-
tion thereof as causal factors. As there is no evidence to
support this extension, AN should be renamed ‘phenacetin
nephropathy’.
In the SAN study, as in most epidemiological studies
on the nephrotoxic role of analgesics, the end-point is not
AN but ESRD. In the absence of validation of evidence of
AN, the term ‘analgesic-associated nephropathy’ (AAN)
is used in most of these studies and, besides AN, a con-
tribution to the progression of existing renal diseases has
been considered as possible. This possibility was most often
considered for acetaminophen [21,27,28], but was not con-
firmed in other studies [1,29]. However, as acetaminophen
is recommended as the analgesic of choice in patients with
renal disease [5], there is an increased risk of confounding
by indication. The inconsistency of the data and the risk of
bias have led to consider the evidence as inconclusive in
several reviews [15,30,31].
The inconsistency of the data when individual analgesics
are considered has led to a further enlargement of the defi-
nition of AAN, including not only single or combined anal-
gesics but also NSAIDs as contributing to the development
or the progression of chronic renal disease of whatever
aetiology [19]. All analgesics and NSAIDs are inhibitors
of cyclooxygenase (COX), and it is tacitly assumed that
they could therefore share the same toxicity for the kid-
ney. It is beyond doubt that all analgesics could influence
renal function. However, using COX inhibition as a com-
mon link to consider together different analgesic drugs, ig-
nores that there are different COXs and that the selectivity
and activity of the inhibition differ from drug to drug (re-
view in [32]). Furthermore, COX inhibition can have pos-
itive as well as negative aspects. For the evaluation of the
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possible effects of COX inhibition on existing renal dis-
eases, different influences should be considered.
1. The influence on homeostasis: five different pros-
taglandins play a major role in the regulation of var-
ious aspects of renal function [33]. In the presence
of reduced renal perfusion, especially in the elderly,
COX-2 inhibition can lead to acute renal failure. The
risk will be dependent on the inhibition ratio COX-
2/COX-1 for the drug considered. As salicylic acid and
acetyl salicylic acid are highly selective for COX-1,
their influence on renal homeostasis will be negligible.
Similarly, acetaminophen does not significantly inhibit
either COX-1 or COX-2 but mainly COX-3, which is
only present in the brain [32]. This influence on the
homeostasis is drug specific and not common to all
COX inhibitors. It is, however, not always negative as
illustrated by the control of Bartter’s syndrome by in-
domethacin administration [34].
2. The influence on pathological processes: Up-regul-ation
of the expression of COX-1 and COX-2 is a response of
the kidney to various aggressions, and especially COX-2
expression is increased in the macula densa and in some
glomerular structures [35]. Influence of cyclooxygenase
inhibitors can therefore be expected. One of the first re-
ported examples of such an influence is the decrease of
proteinuria under treatment with indomethacin [36,37].
This reduction is not only related to a reduction of the
glomerular filtration but also to a restoration of the size-
selectivity barrier [38]. These earlier clinical observa-
tions are now supported by consistent experimental data
[35,39–45]. In contrast with the majority of these ex-
periments showing an improvement in the renal injury,
COX-2 inhibition increased proteinuria and interfered
with the healing process in a model of spontaneously
recovering glomerulonephritis induced by anti-Thy1.1
[46].
Analgesics can also induce drug-specific adverse effects,
unrelated to COX inhibition. Occasional hypersensitivity
and interstitial nephritis can also occur in antipyretic anal-
gesics as a drug-specific complication. Some NSAIDs,
mainly fenoprofen, can in rare cases induce a nephrotic
syndrome with a typical pathological picture of intersti-
tial nephritis [47]. If these specific diseases occur super-
imposed on existing renal diseases, they could influence
the progression to ESRD, without loosing their identity.
Bringing these specific diseases together with AN under
the non-specific common name of AAN could only result
in confusion.
In summary, the simplistic hypothesis of a contribution
to the progression of existing renal diseases, common to
all analgesics or NSAIDs, does not fit in with the clini-
cal and experimental data. The influence of Cox inhibitors
on the progression of existing renal diseases is a complex
process with positive and negative aspects, without a com-
mon pathological or clinical definition. In the absence
of well-defined criteria, the SAN study as well as the
earlier epidemiologic studies does not provide convinc-
ing evidence justifying overstretching the concept AN to
include all possible negative effects of analgesics and
NSAIDs, and consequently the concept of AAN should be
reconsidered.
Conclusion
The present study failed to find evidence that AN was the
cause of ESRD in the group of high users of single or com-
bined analgesics reported in the SAN study. These findings
support the conclusion [23] that AN should be renamed
phenacetin nephropathy. Furthermore, there is no sound
theoretical or clinical justification for maintaining the name
AAN for an entity including, besides phenacetin nephropa-
thy, a contribution by single or combined analgesics and
NSAIDs to the development or the progression of chronic
renal disease of whatever aetiology.
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